SEC Filing Summary: Form 6-K
Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of March 2026. The filing, dated March 10, 2026, incorporates by reference a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.
Financial Metrics
The filing text provided does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing serves solely to distribute the attached press release.
Material Changes
No material financial changes versus prior periods are detailed in the text of this Form 6-K. The document does not provide comparative financial statements or operational metrics.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) but does not include the content of that release. Consequently, no guidance, management commentary, specific risks, contingencies, or unusual items are described in the provided text.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Missing Content: The actual content of the March 10, 2026, press release (Exhibit 99.1) is not included in the provided text and must be reviewed separately for material news.
- Financial Data: This specific filing contains no financial numbers; investors must refer to the latest Form 20-F or quarterly reports for financial performance.
- Registration Statements: The press release is incorporated by reference into multiple Form S-8 registration statements.